Bradykinin B1 receptors in human umbilical vein
References (27)
- et al.
Further analysis of the up-regulation of bradykinin B1 receptors in isolated rabbit aorta by using metabolic inhibitors
Eur. J. Pharmacol.
(1994) - et al.
Formation of prostanoids in human umbilical vessels perfused in vitro
Prostaglandins
(1986) - et al.
Relaxation of isolated arteries by des-Arg9-bradykinin stimulation of B1 receptors
Eur. J. Pharmacol.
(1986) - et al.
In vitro effects of HOE 140 in human bronchial and vascular tissue
Eur. J. Pharmacol.
(1995) - et al.
Cloning and pharmacological characterization of human bradykinin (BK-2) receptor
Biochem. Biophys. Res. Commun.
(1992) Kinin B1 receptors: a review
Immunopharmacology
(1995)- et al.
Pharmacology of kinins: their relevance to tissue injury and inflammation
Gen. Pharmacol.
(1983) - et al.
Expression cloning of a human B1 bradykinin receptor
J. Biol. Chem.
(1994) - et al.
Bradykinin B1 receptors in rabbit aorta smooth muscle cells in culture
Eur. J. Pharmacol.
(1994) - et al.
Effects of vasoactive agents on isolated human umbilical arteries and veins
Am. J. Physiol.
(1972)
Some quantitative uses of drug antagonists
Br. J. Pharmacol. Chemother.
Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo
Br. J. Pharmacol.
Bradykinin B1 receptors in the rabbit urinary bladder: induction of responses, smooth muscle contraction, and phosphatidylinositol hydrolysis
Br. J. Pharmacol.
Cited by (41)
Argentinean Society of Experimental Pharmacology: Brief history and main scientific contributions to the discipline
2016, Pharmacological ResearchCitation Excerpt :He also started his career in the group of Prof. S. Langer’s. His contribution to Pharmacology is currently based in pharmacodynamics mechanistic studies about the prostanoids and other substances (Bradykinin B1 receptor) using the model of the human umbilical vein [107–112]. Prof. Carlos Lanusse.
Prenatal hypoxia enhanced angiotensin II-mediated vasoconstriction via increased oxidative signaling in fetal rats
2016, Reproductive ToxicologyCitation Excerpt :Sixty minutes were allowed for equilibration. 5-HT (10 mM) was applied for each experiment in order to determinate the tissue maximum response [17]. Vessel rings were contracted with cumulatively increasing concentrations of Ang II (10−11−10−5 mol l−1) in approximate one-half log increments.
Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency
2012, Bioorganic and Medicinal Chemistry LettersEndothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: An effective bradykinin inactivation pathway
2011, European Journal of PharmacologyCitation Excerpt :Aminopeptidase P (Xaa-Pro aminopeptidase, EC 3.4.11.9) inactivates bradykinin by hydrolyzing the N-terminal Arg1-Pro2 bond (Simmons and Orawski, 1992). In our human umbilical vein and artery experimental models, bradykinin induces a potent and efficacious vasoconstriction action mediated by bradykinin B2 receptors (Pelorosso et al., 2007; Sardi et al., 1997). Since bradykinin is very short-lived due to extensive enzymatic degradation and its actions on vascular levels are suggested to be of utmost importance, the aim of the present work was to evaluate, by means of functional assays in isolated human umbilical vein, the possible participation of angiotensin-converting enzyme, neutral endopeptidase and aminopeptidase P as a bradykinin inactivating pathway, as well as assess if the endothelial layer is involved in this process.
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation
2011, Bioorganic and Medicinal Chemistry LettersExpression and functional evidence of the prostaglandin F<inf>2α</inf> receptor mediating contraction in human umbilical vein
2009, European Journal of Pharmacology